Cargando…

COVID-19 Infections in Cancer Patients Were Frequently Asymptomatic: Description From a French Prospective Multicenter Cohort (PAPESCO-19)

BACKGROUND: Cancer patients (CPs) are considered more vulnerable and as a high mortality group regarding COVID-19. In this analysis, we aimed to describe asymptomatic COVID (+) CPs and associated factors. METHODS: We conducted a prospective study in CPs and health care workers (HCWs) in 4 French can...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Ke, Raoul, Jean-Luc, Blanc-Lapierre, Audrey, Seegers, Valérie, Boisdron-Celle, Michèle, Bourdon, Marianne, Mahammedi, Hakim, Lambert, Aurélien, Moreau-Bachelard, Camille, Campone, Mario, Conroy, Thierry, Penault-Llorca, Frédérique, Bellanger, Martine M, Bigot, Frédéric
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9021575/ https://www.ncbi.nlm.nih.gov/pubmed/35465469 http://dx.doi.org/10.1177/11795549221090187

Ejemplares similares

COVID-19 Vaccination Campaign in Cancer Patients and Healthcare Workers-Results from a French Prospective Multicenter Cohort (PAPESCO-19)
por: Seegers, Valérie, et al.
Publicado: (2022)

Anosmia but Not Ageusia as a COVID-19-Related Symptom among Cancer Patients—First Results from the PAPESCO-19 Cohort Study
por: Zhou, Ke, et al.
Publicado: (2021)

COVID-19 Infection despite Previous Vaccination in Cancer Patients and Healthcare Workers: Results from a French Prospective Multicenter Cohort (PAPESCO-19)
por: Seegers, Valérie, et al.
Publicado: (2023)

BRAF Non-V600E Mutated Metastatic Colorectal Cancer in a Young Patient: Discussion from a Case Report
por: Moisset, Laure, et al.
Publicado: (2019)

The EPICURE study: a pilot prospective cohort study of heterogeneous and massive data integration in metastatic breast cancer patients
por: Colombié, Mathilde, et al.
Publicado: (2021)

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplification
por: Cayre, Anne, et al.
Publicado: (2007)

aHIF but not HIF-1α transcript is a poor prognostic marker in human breast cancer
por: Cayre, Anne, et al.
Publicado: (2003)

Testing algorithm for identification of patients with TRK fusion cancer
por: Penault-Llorca, Frédérique, et al.
Publicado: (2019)

Irinotecan induces steroid and xenobiotic receptor (SXR) signaling to detoxification pathway in colon cancer cells
por: Basseville, Agnes, et al.
Publicado: (2011)

From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin
por: Pujol, Pascal, et al.
Publicado: (2019)

P-gp expression in brown trout erythrocytes: evidence of a detoxification mechanism in fish erythrocytes
por: Valton, Emeline, et al.
Publicado: (2013)

Circulating proteins as predictive and prognostic biomarkers in breast cancer
por: Veyssière, Hugo, et al.
Publicado: (2022)

Mini-P-gp and P-gp Co-Expression in Brown Trout Erythrocytes: A Prospective Blood Biomarker of Aquatic Pollution
por: Valton, Emeline, et al.
Publicado: (2015)

Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2018)

Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells
por: El Guerrab, Abderrahim, et al.
Publicado: (2020)

Drug–drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure
por: Raoul, J.L., et al.
Publicado: (2023)

Interest and Limits of [(18)F]ML-10 PET Imaging for Early Detection of Response to Conventional Chemotherapy
por: Jouberton, Elodie, et al.
Publicado: (2021)

Development of a Prognostic Tool to Guide the Decision to Extend Adjuvant Aromatase Inhibitors for up to Ten Years in Postmenopausal Early Breast Cancer Patients
por: Moreau-Bachelard, Camille, et al.
Publicado: (2020)

Anti-EGFR monoclonal antibodies and EGFR tyrosine kinase inhibitors as combination therapy for triple-negative breast cancer
por: Guerrab, Abderrahim El, et al.
Publicado: (2016)

PARP Inhibitors: A Major Therapeutic Option in Endocrine-Receptor Positive Breast Cancers
por: Collet, Laetitia, et al.
Publicado: (2022)

Frequent EGFR Positivity and Overexpression in High-Grade Areas of Human MPNSTs
por: Tabone-Eglinger, Séverine, et al.
Publicado: (2008)

Effect of Concomitant Proton Pump Inhibitors with Pazopanib on Cancer Patients: A Retrospective Analysis
por: Moreau-Bachelard, Camille, et al.
Publicado: (2022)

Identification of miR-10b, miR-26a, miR-146a and miR-153 as potential triple-negative breast cancer biomarkers
por: Fkih M’hamed, Insaf, et al.
Publicado: (2015)

Éditorial
por: Giraudeau, B., et al.
Publicado: (2020)

Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC - PACS 01 randomized trial
por: Jacquemier, Jocelyne, et al.
Publicado: (2011)

If Aviation Were in Control of the COVID-19 Response
por: Ephrat, Eyal
Publicado: (2020)

Long-Term Use of Proton Pump Inhibitors in Cancer Patients: An Opinion Paper
por: Raoul, Jean-Luc, et al.
Publicado: (2022)

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring study
por: van de Vijver, Marc, et al.
Publicado: (2007)

SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2018)

Dual SIRT1 expression patterns strongly suggests its bivalent role in human breast cancer
por: Rifaï, Khaldoun, et al.
Publicado: (2017)

The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines
por: Dubois, Clémence, et al.
Publicado: (2019)

Why is appropriate healthcare inaccessible for many European breast cancer patients? – The EBCC 12 manifesto
por: Cardoso, Fatima, et al.
Publicado: (2021)

Chemical biology fluorescent tools for in vitro investigation of the multidrug resistant P-glycoprotein (P-gp) expression in tumor cells
por: Daumar, Pierre, et al.
Publicado: (2023)

Cellular Expression of Cyclooxygenase, Aromatase, Adipokines, Inflammation and Cell Proliferation Markers in Breast Cancer Specimen
por: Basu, Samar, et al.
Publicado: (2015)

Implementing TMB measurement in clinical practice: considerations on assay requirements
por: Büttner, Reinhard, et al.
Publicado: (2019)

The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer
por: Karsli-Ceppioglu, Seher, et al.
Publicado: (2017)

PROCURE European consensus on breast cancer multigene signatures in early breast cancer management
por: Curigliano, Giuseppe, et al.
Publicado: (2023)

Pharmacokinetic and pharmacogenetic determinants of the activity and toxicity of irinotecan in metastatic colorectal cancer patients
por: Rouits, E, et al.
Publicado: (2008)

Refining patient selection for breast cancer immunotherapy: beyond PD-L1
por: Kossai, M., et al.
Publicado: (2021)

BCRP and P-gp relay overexpression in triple negative basal-like breast cancer cell line: a prospective role in resistance to Olaparib
por: Dufour, Robin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_j8um0d9a1o1sg0k0a07oi35m0k